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Annexin A7 is required for ESCRT 
III-mediated plasma membrane 
repair
Stine Lauritzen Sønder1, Theresa Louise Boye1, Regine tölle2,3, Jörn Dengjel  2,3, 
Kenji Maeda1, Marja Jäättelä  1,4, Adam Cohen Simonsen  5, Jyoti K. Jaiswal  6,7 & 
Jesper Nylandsted  1,4
The plasma membrane of eukaryotic cells forms the essential barrier to the extracellular environment, 
and thus plasma membrane disruptions pose a fatal threat to cells. Here, using invasive breast cancer 
cells we show that the Ca2+ - and phospholipid-binding protein annexin A7 is part of the plasma 
membrane repair response by enabling assembly of the endosomal sorting complex required for 
transport (ESCRT) III. Following injury to the plasma membrane and Ca2+ flux into the cytoplasm, 
annexin A7 forms a complex with apoptosis linked gene-2 (ALG-2) to facilitate proper recruitment 
and binding of ALG-2 and ALG-2-interacting protein X (ALIX) to the damaged membrane. ALG-2 and 
ALIX assemble the ESCRT III complex, which helps excise and shed the damaged portion of the plasma 
membrane during wound healing. Our results reveal a novel function of annexin A7 – enabling plasma 
membrane repair by regulating ESCRT III-mediated shedding of injured plasma membrane.
The plasma membrane is composed of a single phospholipid bilayer, which constitutes the boundary between the 
eukaryotic cell and its environment. Unlike prokaryotic cells, which are protected by a cell wall, most eukaryotic 
cells lack a cell wall and are thus more vulnerable to membrane disruptions1. Hence, effective plasma membrane 
repair mechanisms appear to have evolved to cope with membrane lesions and ensure cell survival2,3. The eukar-
yotic repair response utilizes cytoskeletal and endomembrane systems, and involves both membrane fusion, and 
membrane replacement mechanisms4–7. Influx of Ca2+ ions plays a critical role as the initial trigger of repair by 
activating and guiding repair proteins containing Ca2+-binding motifs to the site of injury. Repair of both small 
(<100 nm) and large (micron scale) plasma membrane wounds involve shedding of damaged membrane (ecto-
cytosis), which is facilitated by the endosomal sorting complex required for transport (ESCRT) III8,9.
Members of the annexin (ANXA) protein family are Ca2+-sensitive proteins that regulate various endomem-
brane processes including vesicle fusion, segregation, and compartmentalization and are implicated in plasma 
membrane repair mechanisms5,10. Annexins share the ability to fuse membranes and aggregate vesicles, and this 
function is important during plasma membrane repair to reseal membrane lesions. However, the role of individ-
ual annexin family members in the plasma membrane repair system is, as yet, not well characterized.
Annexins are phospholipid-binding proteins composed of a conserved COOH-terminal core domain con-
taining four structural repeats, on which type-2 Ca2+-binding sites are located11. Upon Ca2+-binding, annexins 
undergo a conformational change allowing them to bind anionic phospholipids in membranes and interact with 
specific effector proteins such as EF-hand S100 proteins via their N-terminal region12. S100 and annexin proteins, 
are overexpressed in various cancers and are associated with poor overall survival, suggesting an enhanced need 
for membrane trafficking and repair in cancer cells13,14.
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Annexin A7 (ANXA7), originally named synexin, was the first annexin to be discovered four decades ago15 
and has since been associated with tumor progression and reduced overall survival in cancers including hepa-
tocellular carcinoma and breast cancer16,17. However, ANXA7 also acts as a tumor suppressor gene in certain 
tumors such as glioblastoma multiforme18, melanoma19 and prostate cancer20. ANXA7 protein was originally 
identified to promote Ca2+-dependent aggregation of isolated chromaffin granules or lipid vesicles15,21, and has 
been implicated in Ca2+-dependent membrane fusion during exocytosis as observed in lung alveolar surfactant 
secretion22,23. Moreover, ANXA7 is associated with Ca2+ homeostasis, cardiac remodeling24, and inflammatory 
myopathies25. Compared to other annexins, ANXA7 contains an extraordinary long hydrophobic N-terminus of 
more than 100 amino acids11, which appears to confer functional specificity and is responsible for interaction with 
the Ca2+-binding EF-hand protein sorcin26.
Here we have identified ANXA7 as a novel plasma membrane repair regulator and examined the behavior of 
ANXA7 upon plasma membrane injury and reconstituted membrane interactions in vitro with purified proteins 
on artificial lipid bilayers. We found that upon plasma membrane damage triggered by digitonin, nine annexin 
family members translocate to the damaged plasma membrane of breast cancer cells. We show that both ANXA5 
and ANXA7 are required for repair in breast cancer cells in addition to our previous results implicating ANXA4, 
ANXA6 and ANXA213, indicating that a network of annexins are participating in the plasma membrane repair 
response. In the light of our previous findings, showing specific roles of individual annexin family members in 
repair including induction of membrane curvature triggered by ANXA4 and ANXA627, and regulation of actin 
accumulation by ANXA2/S100A1113 we hypothesized that ANXA7 plays a distinct function in plasma membrane 
repair. Here we provide evidence that ANXA7 upon plasma membrane injury is recruited to the site of injury 
where it forms a complex with the Ca2+-binding protein apoptosis-linked gene-2 (ALG-2). We demonstrate that 
ANXA7 is required to recruit ALG-2 and ALG-2-interacting protein X (ALIX) to the damaged membrane. Our 
results show that by enabling Ca2+-triggered ALG-2 and ALIX recruitment at the injured plasma membrane, 
ANXA7 initiates the process of ESCRT III buildup at the site of injury, which is needed to shed damaged mem-
brane during the repair process.
Results
Annexin family members are differentially recruited to the plasma membrane upon injury. To 
identify injury-induced changes in the plasma membrane proteome we used MCF7 breast cancer cells expressing 
a N-terminally truncated 95 kDa version of ErbB2 (p95ErbB2), which increases their membrane dynamics and 
invasiveness28,29. MCF7-p95ErbB2 cells were metabolically labeled by stable isotope-labeling by amino acids in 
cell culture (SILAC) and the plasma membrane proteins were tagged by biotin. The cells were then injured in the 
presence of Ca2+, by exposing them to the membrane pore-forming detergent digitonin, and allowed to repair for 
5 min at 37 °C (Fig. 1a). Plasma membrane fragments and associated proteins were purified by biotin-streptavidin 
affinity purification and compared to non-injured conditions by quantitative mass spectrometry analysis8,30. By 
the digitonin-injury approach we identified six known Ca2+-binding proteins amongst the list of ten proteins 
that increased most at the injured plasma membrane including: Copine-1 (CPNE1), ANXA1, ANXA3-A5, and 
ANXA7 (Fig. 1b). Other proteins detected included mRNA turnover protein 4 homolog (MRT4), Ran GTPase-
activating protein 1, Isoform 2 of Mitochondrial ribonuclease P and Histone acetyltransferase type B subunit. 
However, these proteins showed high ratio variability in two independent experiments and thus were not con-
sidered further (Fig. 1b and Supplementary Table S1). Notably, amongst the list of all increased proteins at the 
plasma membrane upon digitonin-triggered injury, nine belonged to the annexin family including: ANXA1-A7, 
ANXA9, and ANXA11. Of these, ANXA4, ANXA5 and ANXA7 showed the highest fold increase in two inde-
pendent experiments (Supplementary Fig. S1a). While distinct roles of ANXA4 and ANXA5 in plasma mem-
brane repair has been demonstrated previously27,31, the function of ANXA7 is, yet, not characterized. Considering 
the localization of annexins to plasma membrane upon injury and extracellular vesicles32,33 we examined the 
involvement of ANXA7 in plasma membrane repair.
ANXA7 depletion compromises repair of MCF7-p95ErbB2 cells. To monitor the behavior of ANXA7 
in response to plasma membrane injury, HeLa cells expressing ANXA7-GFP or MCF7-p95ErbB2 co-expressing 
ANXA7-RFP and ANXA1-GFP/or ANXA5-GFP were exposed to local membrane injury by focal laser. 
ANXA7-GFP started accumulating at the repair site within 20 s, reaching a maximum accumulation by 80–120 s, 
whereas ANXA1-GFP and ANXA5-GFP peaked already after 30 s in MCF7-p95ErbB2 cells (Figs 1c–e and S1b). 
Thus, ANXA7 shows slower translocation velocity to the site of injury as compared to ANXA1 and ANXA5. 
Interestingly, ANXA1 appeared to enhance the translocation speed of ANXA7 in these experiments (Figs 1d,e 
and S1b). We then investigated whether ANXA7 is needed for repair by monitoring the kinetics of entry of the 
membrane-impermeable FM1-43 dye into MCF7-p95ErbB2 cells following the above focal laser injury approach. 
Use of ANXA7-specific siRNA allowed >90% knockdown of ANXA7, which compromised plasma membrane 
repair, as compared to control siRNA transfected cells (Fig. 1f–h). The compromise in repair kinetics following 
ANXA7 depletion was similar to that of cells depleted for S100A11 – a protein which we have previously revealed 
is required for the repair of MCF7-p95ErbB2 cells13 (Fig. 1g). In a similar assay we measured repair kinetic in 
cells depleted for either ANXA5 or ANXA7, or in cells depleted for both ANXA7 and ANXA5 by siRNAs. While 
ANXA5 or ANXA7 depletion compromised repair, ANXA5/ANXA7 dual depletion impaired repair slightly 
more (Supplementary Fig. S1c,d). In a complementary plasma membrane repair assay, MCF7-p95ErbB2 cells 
were injured by membrane pore-forming detergent - digitonin and assayed for membrane repair by monitor-
ing the cell’s ability to exclude membrane-impermeable dye - propidium iodide. MCF7-p95ErbB2 cells depleted 
for ANXA7 or ANXA5 were poorer at repairing their permeabilized plasma membrane, further supporting 
the requirement of ANXA7 and ANXA5 for maintaining plasma membrane integrity in MCF7-p95ErbB2 cells 
(Supplementary Fig. S1e).
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ANXA7 is required to position ALG-2 at the site of repair. To gain insight into the mechanism by 
which ANXA7 regulates repair, and in the light of the potential interaction between the ESCRT III regula-
tor, ALG-2 and the N-terminal end of ANXA734 we monitored ANXA7-GFP and ALG-2-RFP translocation 
upon laser injury in MCF7-p95ErbB2 cells. Interestingly, ANXA7-GFP accumulated at the damaged mem-
brane and co-localized with ALG-2-RFP at the site of injury and similar translocation pattern was observed for 
ANXA7-RFP/ALG-2-GFP (Fig. 2a,b and Supplementary Fig. S2a and Movie S1). To test interaction between 
ANXA7 and ALG-2 proteins, we carried out co-immunoprecipitation (co-IP) experiments in MCF7-p95ErbB2 
cells overexpressing ANXA7-RFP or ANXA7-GFP using anti- mRFP or tGFP antibodies (Figs 2c and S2c). 
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Figure 1. ANXA7 is needed for repair in MCF7-p95ErbB2 cells. (a) Schematic representation of the proteomic 
setup. MCF7-p95ErbB2 cells were cultured in SILAC medium. Cells were left uninjured (control) or injured 
by treating with digitonin (20 µg/ml) for 10 min at 37 °C. Cells were disrupted and biotin labelled membrane 
fragments were affinity purified using streptavidin beads before MS analysis. (b) Plot showing change in 
cell surface level of proteins presented as the ratio of MCF7-p95ErbB2 cells treated with digitonin over 
uninjured MCF7-p95ErbB2 as measured by MS analysis (Also see Supplementary Fig. S1A and Table 1). (c) 
Representative sequential images of HeLa cells showing the translocation of ANXA7-GFP or (d) ANXA7-RFP 
and ANXA1-GFP (upper panel) or ANXA7-RFP and ANXA5-GFP (lower panel) in MCF7-p95ErbB2 cells in 
response to focal laser injury (blue arrow indicates injury site). (e) Corresponding translocation kinetic plots. 
Error bars represent SEM from three independent experiments. (f) Immunoblot showing ANXA7 and S100A11 
protein levels in MCF7-p95ErbB2 depleted for ANXA7 or S100A11, as compared to Ctrl siRNA. HSP90 served 
as loading control (72 h). (g) Plasma membrane repair kinetics upon laser injury measured by membrane 
impermeable FM1-43 dye influx in MCF7-p95ErbB2 transfected with ANXA7, S100A11 or Ctrl siRNA for 72 h. 
Error bars represent SEM for at least 10 independent cells per condition. (h) Representative images of MCF7-
p95ErbB2 cell transfected with either Ctrl siRNA (upper panel) or ANXA7 siRNA (lower panel) showing the 
influx of impermeable FM1-43 dye after laser injury (white arrow indicates injury site). The asterisk represent 
P-values based on Student’s t-test (g): **P ≤ 0.01, as indicated when comparing indicated siRNAs to control 
siRNA. Full-length blots are presented in Supplementary Fig. S2b.
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Figure 2. ANXA7 is needed for positioning ALG-2 at the repair site. (a) Representative sequential images of 
MCF7-p95ErbB2 cell expressing ALG-2-RFP and ANXA7-GFP exposed to laser injury (blue arrow indicates 
injury site) and (b) corresponding kinetic blot from three independent experiments. Error bars represent 
SEM. Also, see Supplementary Movie 1. (c) Representative immunoprecipitation experiment using RFP, GFP, 
ALG-2 or control IgG antibodies from lysates of MCF7-p95ErbB2 cells overexpressing ANXA7-mRFP or 
ANXA7-tGFP and exposed to scrape injury. Following IP, immunoblot analysis was carried out using ANXA7 
and ALG-2 antibodies. (d) Representative sequential images of the translocation of ALG-2-GFP in response to 
laser injury (blue arrow indicates injury site) in MCF7-p95ErbB2 cells transfected with control siRNA (upper 
panel) or ANXA7 siRNA (lower panel) (72 h). (e) Time for peak of ALG-2 accumulation at the repair site 
following laser injury of MCF7-p95ErbB2 transfected with indicated siRNAs (72 h). Error bars represent SD 
for 10 independent cells per condition. The asterisk represent P-values based on Student’s t-test: **P ≤ 0.01. (f) 
Immunoblot showing ANXA7 and p95ErbB2 protein levels in MCF7-p95ErbB2 Ctrl-CRISPR cells as compared 
to A7-CRISPR cells. Tet– refers to cells washed to remove tetracycline to induce p95ErbB2 expression. HSP90 
and CDK7 served as controls for equal loading. (g) Cell membrane repair kinetics upon laser injury measured 
by membrane impermeable FM1-43 dye influx in MCF7-p95ErbB2 Ctrl-CRISPR cells as compared to A7-
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Following scrape injury, ANXA7 was able to co-IP endogenous ALG-2 using both, tGFP and mRFP anti-
bodies (Fig. 2c), whereas siRNA-depletion of ALG-2 reduced ANXA7 co-immunoprecipitation of ALG-2 
(Supplementary Fig. S2e). Thus, these results suggest that ANXA7 and ALG-2 can form a complex in injured cells.
To examine if ANXA7 is required for injury-triggered trafficking of ALG-2 at the site of injury, we moni-
tored the ALG-2-GFP response to injury following siRNA-mediated depletion of ANXA7 in MCF7-p95ErbB2 
cells. Lack of ANXA7 (<10%) delayed the translocation of ALG-2-GFP to the site of injury, and unlike the con-
trol cells where ALG-2 cleared out from the injury site, in ANXA7 depleted cells ALG-2 remained accumulated 
in a spatially diffuse manner around the injured membrane (Fig. 2d,e). To complement this further we gener-
ated MCF7-p95ErbB2 cells with CRISPR/cas9 disrupted ANXA7 gene expression (A7-CRISPR) (Fig. 2f,g) and 
attempted to rescue the ANXA7 knockout phenotype by re-expressing ANXA7-RFP or Ctrl-RFP. ANXA7-RFP 
reversed the slower translocation of ALG-2-GFP to the injury site (Figs 2h,i and S2d), and caused localized accu-
mulation of ALG-2-GFP at the injury site (Fig. 2h, right panel and Fig. 2j). In contrast, expression of Ctrl-RFP 
resulted in a diffuse and more widespread distribution of ALG-2-GFP in cells indicating that its localization at the 
damaged membrane depends on ANXA7 (Fig. 2h, left panel and Fig. 2j). Since ALG-2 mediates injury-triggered 
ALIX accumulation8, we next examined if ANXA7 knockout also alters ALIX accumulation at the site of injury. 
Simultaneous imaging of ALIX-GFP and ANXA7-RFP or Ctrl-RFP in A7-CRISPR cells showed that in the 
Ctrl-RFP expressing cells, ALIX-GFP accumulated in a spatially diffuse manner (similar to ALG-2), whereas 
expression of ANXA7-RFP caused co-localized accumulation of ALIX-GFP at the site of damage (Fig. 2k,l). Thus, 
ANXA7 appears to be required for proper temporal and spatial translocation of ALG-2 and ALIX to the site of 
injury.
ALG-2 is dependent on ANXA7 for membrane binding. To examine the ability of ANXA7 to recruit 
ALG-2 directly on membranes we attempted to reconstitute this process in vitro. We generated recombinant 
ANXA7 and ALG-2 proteins and used them together with artificial solid supported lipid membrane patches 
formed by hydration of the dry precursor lipid film35. These membrane patches contain freestanding edges allow-
ing us to model the edge of an injured plasma membrane (Fig. 3a). Recombinant ANXA7-GFP protein added 
to these membranes accumulated locally (in <4 min) at the free membrane edges into a pearl-like pattern and 
caused these edges to curve (Fig. 3b and Supplementary Movie S2). This effect of ANXA7 required presence of 
Ca2+ and negatively charged phosphatidylserine in the membrane (Fig. 3c). Adding recombinant ALG-2-GFP 
protein to these freestanding membranes showed that ALG-2 failed to bind or have any effect on membrane 
conformation, demonstrating the inability of ALG-2 to bind the membrane on its own (Fig. 3d). However, when 
recombinant ALG-2-GFP and ANXA7 proteins were co-incubated, ALG-2-GFP accumulated into pearl-like 
structures at the free membrane edges (Fig. 3e). Taken together, these results show that ANXA7 binds to the free 
membrane edges in a Ca2+- and phosphatidylserine-dependent manner and facilitates ALG-2 binding to the 
membrane.
ANXA7 is required for ESCRT III mediated shedding of damaged membrane. While we find that 
the artificial membrane edges bind ANXA7/ALG-2 complex, we have previously identified that ALG-2 ena-
bles membrane shedding in vivo by facilitating accumulation of ALIX and ESCRT III protein complex at the 
injured plasma membrane8. To elucidate this in cells we tested if an ANXA7 mutant (ANXA7ΔN99) lacking 
99 amino acids of the N-terminal region responsible for ALG-2 binding while maintaining the core annexin 
domains intact, can facilitate injury-triggered ALG-2 accumulation at the injury site34,36. MCF7-p95ErbB2 
A7-CRISPR cells were transfected with ALG-2-GFP and either full length ANXA7-RFP or ANXA7ΔN99-RFP. 
Full-length ANXA7 and ALG-2 complex accumulated at the injury site and was subsequently shed with damaged 
membrane as the cell repaired (Fig. 4a–c). In contrast, ANXA7ΔN99-RFP mutant failed to translocate to the 
injured membrane, which prevented translocation of ALG-2 to the site of injury (Fig. 4d-f). This demonstrates 
that the N-terminus of ANXA7 is important for translocation to the damaged membrane and Ca2+-mediated 
membrane binding of ALG-2, as suggested previously36. In response to ANXA7/ALG-2 binding, vesicles were 
typically shed within 2–15 min (Fig. 4g, Supplementary Movies S3–S5) as monitored by confocal imaging in 
accordance with previous studies8,9. Next, we monitored the shedding frequency upon laser injury. While 70% of 
cells with wildtype ANXA7-RFP shed their injured plasma membrane, this only occurred in 15–20% of Ctrl-RFP 
or ANXA7ΔN99-RFP expressing cells (Fig. 4h). Moreover, the number of shedded vesicles were significantly 
reduced in the ANXA7ΔN99-RFP mutant as compared to wildtype ANXA7-RFP, whereas the size of shedded 
CRISPR cells (A7-CRISPR cells show compromised repair). Error bars represent SD for at least 7 independent 
cells per condition. (h) Representative images of translocation behavior of ALG-2-GFP upon focal laser injury 
(blue arrow indicates injury site) in MCF7-p95ErbB2 A7-CRISPR cells expressing Ctrl-RFP plasmid (left 
panel) or wildtype ANXA7-RFP (right panel). (i) Time for ALG-2 to reach injury site in MCF7-p95ErbB2 A7-
CRISPR cells expressing Ctrl-RFP plasmid or wildtype ANXA7-RFP. (j) ALG-2-GFP distribution (µm2) or (k) 
ALIX-GFP distribution (µm2) around the injured membrane in A7-CRISPR cells expressing either Ctrl-RFP or 
ANXA7-RFP measured by Volocity software. (l) Representative sequential images of ALIX-GFP translocation 
upon laser injury (blue arrow indicates injury site) in MCF7-p95ErbB2 A7-CRISPR cells expressing Ctrl-
RFP plasmid (left panel) or wildtype ANXA7-FP (right panel). Note, ANXA7-RFP tend to form unspecific 
aggregates when overexpressed (red puncta around the nucleus). The aggregates are inert and do not respond 
to membrane injury. White line indicates region of interest (ROI). Error bars represent SD for at least 5–6 
independent experiments. P-values based on Student’s t-test: ***P ≤ 0.001. Full-length blots for 2c and 2f are 
presented in Supplementary Figs S2c and S3 respectively.
6Scientific RepoRts |          (2019) 9:6726  | https://doi.org/10.1038/s41598-019-43143-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
vesicles were similar in the two conditions (Fig. 4i,j). Since ALG-2 enables ALIX-mediated recruitment of ESCRT 
III protein complex at the injured plasma membrane8, we used live cell imaging to monitor the behavior of 
Chmp4b – a core component of the ESCRT III complex. Upon injury, MCF7-p95ErbB2 Ctrl-CRISPR cells accu-
mulated Chmp4b-YFP puncta at the damaged membrane within 240 s, whereas MCF7-p95ErbB2 A7-CRISPR 
cells were impaired in their ability to localize Chmp4b at the repair site (Fig. 4k,l). These results suggest that 
ANXA7 is responsible for binding and positioning ALG-2 and ALIX to the injured membrane and this function 
is important for assembly of ESCRT III components and subsequent shedding of damaged membrane.
Discussion
Our proteomic analysis of invasive breast cancer cells shows that annexin family members are amongst the pro-
teins that show greatest enrichment at the plasma membrane during repair. Differences in the enrichment of 
annexins at the plasma membrane may be due to variances in their Ca2+-sensitivity37 and their binding affinity to 
Figure 3. ANXA7 is required for ALG-2 binding to supported membranes. (a) Schematic representation of 
supported membrane model composed of primary and secondary membranes. Non-vesicular membrane 
patches with open edges were used in the subsequent experiments (POPC/POPS, 9:1 molar ratio). (b) 
Representative sequential images before and after addition of recombinant ANXA7-GFP protein to a membrane 
patch stained with DiD (DiD channel: upper panel. Lower panel: GFP channel) in the presence of Ca2+ (Also 
see Supplementary Movie S2). Note, ANXA7-GFP induces a pearl-like membrane conformation. (c) Similar 
experiment as in b but in the absence of Ca2+ (top panel) or POPS (lower panel). (d) Sequential images before 
and after addition of recombinant ALG-2-GFP protein to a membrane patch stained with DiD in the presence 
of Ca2+. (e) Addition of ANXA7 (without GFP) and ALG-2-GFP proteins trigger ALG-2-GFP membrane 
binding. Accumulation of ALG-2-GFP into pearl-like peripheral structures induced by ANXA7 are indicated by 
yellow arrows (upper panel, DiD. Lower panel: GFP channel).
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Figure 4. ANXA7 is needed for Chmp4b buildup and ectosome shedding. (a) Representative sequential images 
of the translocation behavior and shedding of ANXA7-RFP and ALG-2-GFP in MCF7-p95ErbB2 A7-CRISPR 
upon localized laser injury and corresponding intensity plots of proteins intracellularly (b) or extracellularly 
(c) measured by Volocity software (blue arrow indicates injury site). (d-f) similar experiment as in a, but with 
ANXA7 mutant (A7ΔN99) lacking most of the N-terminus. Note, this mutant have decreased Ca2+-sensitivity 
and shedding activity and fail to localize ALG-2-GFP at the injured membrane. (g) Typical sequential images 
showing ANXA7-RFP/ALG-2-GFP translocation to injured membrane and subsequently excision and 
shedding of membrane containing protrusions. (h) Cell shedding frequency in MCF7-p95ErbB2 A7-CRISPR 
cells expressing Ctrl-RFP, wildtype ANXA7-RFP or A7ΔN99-RFP mutant. Error bars represent SD for at least 
15 independent cells per condition. P-values based on Student’s t-test: ***P ≤ 0.001. (i) Number of shedded 
vesicles as measured from the very edge of the cells membrane upon laser injury of MCF7-p95ErbB2 A7-
CRISPR cells expressing wildtype ANXA7-RFP or A7ΔN99-RFP mutant. Cells were injured at the very edge of 
the cell membrane and shedded vesicles captured by time lapse imaging (Also see Supplementary Movies S3–
S5). (j) Average vesicle diameter of shedded vesicles after laser injury. Examples of vesicle diameter indicated in 
a and c. Data were obtained from time-lapse movies using Volocity software. SD for at least 4 experiments. (k) 
Typical sequential images of Chmp4b-YFP translocation in MCF7-p95ErbB2 Ctrl-CRISPR or A7-CRISPR cell 
upon laser injury. (l) Graph showing Chmp4b-YFP translocation kinetic at the site of injury in MCF7-p95ErbB2 
Ctrl-CRISPR and A7-CRISPR cells. Error bars represent SEM for at least 8 independent cells per condition. 
P-values based on Student’s t-test: **P ≤ 0.01.
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the plasma membrane. Annexin family members have been associated with plasma membrane repair, but their 
precise mechanisms of action are poorly characterized5. It seems plausible that several annexins act in concert 
to repair the damaged membrane, which our data support. However, besides their shared ability to aggregate 
and fuse membranes, which is important for repair, annexins appear to serve more specific functions in plasma 
membrane repair5. Previously we have shown that annexin family member, ANXA2 together with its binding 
partner S100A11, stabilizes the injured plasma membrane by facilitating F-actin buildup at the wound site13. 
This role of ANXA2 in MCF7-p95ErbB2 cells is distinct from our more recent finding of a biophysical role of 
ANXA427, another annexin family member that we find is highly enriched at the repairing plasma membrane. 
ANXA4 is recruited to the damaged membrane and homo-trimerizes at the wound edges, inducing membrane 
curvature. This curved membrane then undergoes constriction by ANXA6, which helps pull the wounded mem-
brane edges together for eventual closure27. Here, we add further to the specialized annexin functions during the 
repair process, which helps cells to cope with membrane disruptions. We show that a novel function of annexin 
family member ANXA7 is to facilitate ESCRT III-mediated shedding of the damaged edges of the wounded 
plasma membrane, enabling membrane repair. ANXA7 facilitates this by regulating the binding of ALG-2 to the 
injured plasma membrane. ALG-2 in turn enables recruitment of ALIX, which then directly binds and recruits 
the ESCRT III proteins8. Thus, ANXA7 appears to be part of the early repair response, regulating proper localiza-
tion of ALG-2 and ALIX at the damaged membrane. This is supported by in vitro reconstitution of ANXA7 facil-
itated recruitment of ALG-2 in the tethered membrane patch approach. ANXA7 and ALG-2 accumulate locally 
at the edge of the membrane patch, causing formation of a pearl-like pattern of the bound membrane triggered 
by ANXA7. This ability is unique for ANXA7 and ANXA11 as compared to other annexin family members and 
involve induction of local membrane curvature as measured by atomic force microscopy35. The pearl/lens struc-
tures are fluid, mobile, and predominantly nucleated near the membrane edges where they appear to co-localize 
with phosphatidylserine lipid between the two membrane leaflets in the bilayer. The occasional rupture of lenses 
and release of their content suggests that they encapsulate a hydrophobic complex of phosphatidylserine and 
annexin such as reverse micelles or a related geometry35. Formation of big fluid lenses is only associated with 
the tethered membrane patch model and, hence is not observed in cells. However, in cells ANXA7 forms local 
pearl-like structures together with ALG-2 at the damaged membrane before buildup of ESCRT III complex. 
Since membrane bending is canonical for ESCRT III-mediated abscission38, ANXA7 might help in this process 
by inducing local membrane curvature needed to initiate ESCRT III complex-assembly and subsequently local 
shedding of membrane in the form of ectosomes. However, the exact nature of this mechanism remains to be 
fully elucidated.
Based on our results we propose a model that depicts the steps in the repair response (Fig. 5). In resting cells, 
ANXA7, ALG-2, ALIX, and ESCRT III proteins are all predominantly cytosolic. Following plasma membrane 
injury, influx of Ca2+ into the cytoplasm causes ALG-2 to bind to the N-terminal region of ANXA7 and form a 
complex with ALIX, which is anchored to the injured membrane through the phospholipid-binding core domain 
of ANXA7. Here, ALG-2/ALIX initiate the assembly of ESCRT III components by recruiting ESCRT III members 
such as Chmp4b. The ESCRT III proteins may then assemble spirally around the curved membrane followed by 
contraction, which lead to the shedding of the damaged membrane edges in way of ectosomes (Fig. 5). With the 
ubiquity of ANXA7 expression and plasma membrane injury, the role of ANXA7 in mediating plasma membrane 
Figure 5. Proposed model for plasma membrane repair mediated by ANXA7. 1. In resting cells ANXA7, 
ALG-2 and ALIX are predominantly cytosolic. 2. Following plasma membrane injury and influx of Ca2+ 
into the cytoplasm ANXA7, ALG-2 and ALIX forms a complex, which is anchored to the injured membrane 
through the core domain of ANXA7. 3. Here, ALG-2 and ALIX initiates the sequential assembly of ESCRT III 
components by recruiting Chmp4 proteins including Chmp4b, which assemble into membrane bound spring-
shaped filaments. 4. Membrane excision occur upon contraction of the spiral structure leading to shedding of 
the damaged membrane. Other annexin family members including ANXA4, ANXA5 and ANXA6 participate 
in the repair network and are needed for wound healing (not shown here).
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repair by recruiting ESCRT III machinery may be broadly relevant, but heightened further in invasive breast 
cancer cells. Thus, our work here identifies a novel role of ANXA7 in cell survival, which may open for novel 
approaches to target aggressive breast cancer cells by inhibiting plasma membrane repair.
Methods
Cell culture and treatments. HeLa cells originating from cervix carcinoma (ATCC) were cultured in 
RPMI 1640 GlutamaxTM medium (Gibco) supplemented with 6% heat-inactivated fetal calf serum (Biological 
Industries), penicillin and streptomycin. MCF7-p95ErbB2 cell line is single cell clone of MCF7 cells stably 
expressing the tetracycline transactivator with a truncated version of ErbB2 (p95ErbB2) in the pTRE plasmid39. 
p95ErbB2 expression is induced by washing off tetracyclin (1 µg/mL) with PBS. All cells were kept at 37 °C in a 
humidified atmosphere of 5% CO2. The experiments were carried out at 3–5 passage after the induction and in all 
the experiments with p95ErbB2 refers to induced cells.
siRNAs and plasmid transfection. siRNA transfections were performed using oligofectamineTM trans-
fection reagent (ThermoFischer) with 25 nM siRNA (Sigma-Aldrich), according to the manufacturer’s protocol. 
siRNA sequences: Control siRNA (AllStar Negative Control siRNA, Qiagen), ANXA5 (ANXA5#1: 5′-GCA ACU 
ACU CCU UGC UGUU[dT][dT]-3′, ANXA5#2: 5′-GUG AGA UUG AUC UGU UUAA[dT][dT]-3′), ANXA7 
(ANXA7#1: 5′-CUU CAU GCC UCC UAC GUAU[dT][dT]-3′, ANXA7#2:5′-GCU UAU UCU AGG AUG 
GCUA[dT][dT]-3′), S100A11#1 (5′-ACU CUC UCC AAG ACA GAG UUC CUAA-3′), ALG-2 (5′-CAC GAC 
AUC CUC AUU CGAA[dT][dT]-3′). For plasmid transfection, cells were transiently transfected with the indi-
cated plasmid using LipofectamineTM LTX transfection reagent (ThermoFischer) 24 h before experimentation, 
according to the manufacturer’s protocol.
Immunoblotting, immunoprecipitation and antibodies. Cells were extracted in SDS-lysis buffer and 
proteins separated by SDS–PAGE using precast 4–15% gradient gels (BioRad) and blotted onto nitrocellulose 
membranes (BioRad) using Trans-Blot TurboTM transfer system and blocked in 5% milk. Primary antibodies 
raised against human ANXA7 (1:1000 dilution, ab49838, Abcam), ALG-2 (PDCD6, 1:1000 dilution, ab133326, 
Abcam) ANXA5 (1:1000 dilution, ab54775, Abcam or 1:1000 dilution ab14196, Abcam), S100A11 (1:1000 dilu-
tion, 10237-1-AP, Proteintech Europe), ErbB2 (HER-2/c-erbB-2/neu Ab-17, 1:1000 dilution, MS-730-P0-A, 
ThermoFisher Scientific), Heat-shock protein 90 kDa (Hsp90, 1:4000 dilution, 610418, BD Transduction 
Laboratories™), GAPDH (1:5000 dilution, ab189095 Abcam), CDK7 (MO-1 was kindly provided by Jiri Bartek), 
were used followed by appropriate peroxidase-conjugated secondary antibodies (DAKO). Immunoprecipitation: 
Lysates from MCF7-p95ErbB2 cells overexpressing ANXA7-monomericRFP or ANXA7-turboGFP were har-
vested in lysis buffer (50 mM Tris-HCl pH (7.4), 150 mM NaCl, 0. 5% Np40 (IGEPAL), 1 mM EDTA) supple-
mented with 1X protease (Roche) and phosphatase (Active Motif) inhibitors. Proteins were immunoprecipitated 
from whole cell lysate using 3 µg antibody (tGFP, TA150041, Origene) coupled to protein A agarose beads 
(Millipore) or using RFP-Trap agarose beads (Chromotek) for o/n at 4 °C according to the manufacturer’s instruc-
tions. The precipitates were washed four times and eluted with 2XLSB with 100 mM dithiothreitol (DTT).
Plasmid constructs and recombinant proteins. Expression plasmids with turbo-GFP C-terminal tag 
containing human ANXA5, ANXA7 or ALG-2 cDNA were purchased from OriGene Technologies, and flu-
orescently tagged ALG-2 (RFP) plasmid was kindly provided from Hideki Shibata (Nagoya University) and 
Chmp4b-(YFP) from Martin Serrano (University College London). ANXA1-GFP was kind gift from Annette 
Draeger. ANXA7 with monomeric RFP C-terminal tag was made by subcloning of ANXA7 cDNA into the mam-
malian pCMV- AC-mRFP vector (OriGene). ANXA7 deletion mutants lacking amino acids 2–100 (ΔN99) of 
the N-terminal region were generated by PCR-based site-directed mutagenesis using QuikChange Lightning 
Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s protocol. Primer sequences 
for generation of deletion mutant: ANXA7ΔN99, Forw. 5′-GCC GCG ATC GCC ATG GGC TTT TCT GGG 
TAT-3′; Rev. 5′-ATA CCC AGA AAA GCC CAT GGC GAT CGC GGC-3′. Recombinant proteins were pro-
duced from ANXA7 cDNA constructs subcloned into the bacterial pEX-C-His vector (OriGene). Moreover, 
for C-terminal GFP-tagged proteins ANXA7 and ALG-2 cDNA were subcloned into pETM11SUMO3sfGFP40. 
Proteins were produced using Immobilized Metal-Affinity Chromatography (IMAC) followed by fast protein liq-
uid chromatography (FPLC). Targeted gene disruption of ANXA7 expression in MCF7-p95ErbB2 cells was per-
formed by CRISPR/Cas9 system with the following target sequences: 5′-CGTCTCTATCAAGCTGGTGAGG-′3. 
Cells were transfected with the All-in-One CRISPR/Cas9 plasmid (SigmaAldrich) using LipofectamineTM LTX 
(ThermoFischer) according to the manufacturer’s protocol and cell-sorted for GFP expression to obtain single cell 
clones. Clones were verified for disruption of reading frame by sequencing and analyzed for protein expression.
Quantitative SILAC mass spectrometry. For SILAC labeling: MCF7-p95ErbB2 cells were cultured for at 
least 6 generations in medium containing regular Lysine and Arginine isotopes (unlabelled) or with media con-
taining 13C6 Arginine and 15N2,13C6 Lysine as the sole source of these amino acids (labelled) (Silantes Gmbh). 
Biotin-labeling of cell surface proteins: Cells grown in 150 mm dishes (approx. 1.5 × 107 cells) were washed 
three times in ice cold HBSS (+Ca2+) (Gibco) and incubated for 30 min on ice at 4 °C on a rocking table with 
5 mL of HBSS (+Ca2+) containing 1 mg/mL (approx. 2 mM biotin reagent) EZ-Link sulfo-NHS-LC-LC-Biotin 
(ThermoFisher) according to the manufacturer’s protocol. Cells were washed three times with cold HBSS 
(+Ca2+). Then cells were treated with 20 µg/mL digitonin (Sigma-Aldrich) in HBSS (+Ca2+) for 10 min at 37 °C. 
Control cells were quickly harvested in 10 mL cold HBSS (−Ca2+) and spun down. Control and injury treated 
cells were mixed and resuspended in 1 mL cold HBSS (+Ca2+) supplemented with protease (Roche) and phos-
phatase (Active Motif) inhibitors. Cells were disrupted by glass beads by vortexing for 2 min and kept on ice. 
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Lysate were then spun down (750 × g at 4 °C for 10 min) to remove of nuclei and unbroken cells and the super-
natant was isolated. The supernatant (=light membrane fraction including plasma membrane fragments) was 
incubated with 100 µl pre-equilibrated streptavidin agarose beads (Invitrogen) and incubated for 1 h at 4 °C with 
rotation followed by three washes in HBSS (+Ca2+) supplemented with protease inhibitors. Proteins were eluted 
in 2xLSB +5% DTT (Sigma-Aldrich) and boiled at 97 °C for 8 min. Samples were concentrated on a 10 kDa 
cutoff filter (Sartorius) and disulfide bonds were reduced with 1 mM DTT and alkylated using 5.5 mM iodoaceta-
mide (Sigma–Aldrich) for 30 min at 25 °C. Proteins were separated by 4–12% Bis–Tris gradient SDS–PAGE gels 
(Invitrogen). Gel lanes were cut into 10 fractions and proteins therein were digested with trypsin41 (Promega). 
Peptide solutions were desalted on STAGE Tips as described42.
Mass Spectrometry: Peptides were analysed with a LTQ Orbitrap XL mass spectrometer (Thermo Fisher 
Scientific) essentially as described43. Briefly, an Agilent 1200 nanoflow–HPLC with a fused silica column packed 
in- house with Reprosil–Pur 120 ODS–3 (Dr. Maisch) was used for peptide separation prior to MS analysis. Data 
was acquired in the data–dependent mode and switched automatically between MS and MS/MS whereas a maxi-
mum of  1 × 106 ions in MS was allowed. MaxQuant based identification and quantification of proteins
MaxQuant software version 1.4.1.2.44 was used for raw mass spectral data search for identification and quan-
tification of peptides and proteins using default settings with minimally one unique peptide used for protein 
identification. Implemented in MaxQuant was a UniProt Homo Sapiens database from July 2015.
Membrane wounding experiments. Laser injury assay: cells were injured at 37 °C in cell imaging 
media (CIM: Hank’s balanced salt solution +10 mM Hepes +2 mM Ca2+, pH 7.4) by pulsed UV-laser (Rapp 
OptoElectronic or visible light (532 nm)-laser (AblateTM, 3i Intelligent Imaging Innovations, Inc. Denver, 
CO, USA) by irradiating a small region (1–2 µm2) for <10–100 ms. The injury response was imaged with a 
63x objective using either Nikon confocal microscope equipped with a PerkinElmer spinning disk (for Rapp 
OptoElectronic pulsed UV-laser) or IX81 Olympus microscope equipped with a Yokogawa spinning disk con-
focal system (for AblateTM pulsed UV laser). The cells were imaged every 4–10 s starting before injury and 
continuing up to 20 min following injury. Microscope hardware Olympus or Nikon was controlled by Slidebook 
5.0 (Intelligent Imaging Innovations Inc., Denver) or Volocity (PerkinElmer), respectively. Slidebook or Volocity 
software was used to measure kinetic of repair by monitoring uptake of impermeable cellular FM1-43 dye (Life 
technologies) (1 mg/mL) as a change in fluorescence during the course of imaging. Volocity was used to analyze 
the translocation kinetic for ANXA7, ALG-2 and Chmp4b after injury, measure distribution of ALG-2 and ALIX 
after injury and measure cell shedding frequency. To measure membrane integrity upon digitonin permeabiliza-
tion cells were incubated with 2.5 µg/mL Hoechst-33342 (Life Technologies) (Excitation 350, Emission 461) and 
2 µg/mL propidium iodide (Sigma-Aldrich) (Excitation 535, Emission 617) and integrity was measured using 
Celigo cytometer (Brooks Life Science Systems) according to the manual and analyzed using Celigo Software 
Version 2.1.
Supported membrane experiments. Sheets of mica substrates (5 × 5 mm2, Plano GmbH) were glued to 
glass coverslips (Ø24 mm, 0.17 mm thick) using the silicone elastomer MED-6215 (Nusil Technology). A droplet 
(40 µL) of the lipid stock was applied to the freshly cleaved mica, spun on a spincoater and placed under vacuum 
in a desiccator (10–12 hours) to ensure evaporation of the solvent. Dry spin-coated lipid films composed of phos-
phatidylcholine (POPC; 1-hexadecanoyl-2–(9Z-octadecenoyl)-sn-glycero-3-phosphocholine) and phosphati-
dylserine (POPS; 1-hexadecanoyl-2–(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine) (Avanti) (or without 
POPS) were prepared from a stock solution containing 10 mM total lipid (POPC, POPS, 9:1 molar ratio) and 0.5% 
DiD probe (Avanti). The spincoated lipid film was hydrated in 50 mM TRIS buffer (2-Amino-2-(hydroxymethyl)
propane-1,3-diol), 100 mM NaCl, +/−2 mM CaCl2, pH = 7.4 at 55 °C for 2 hours. Then the sample was gently 
flushed with 55 °C buffer and buffer exchanged >10 times to prepare defined secondary bilayer patches resting on 
a continuous primary membrane. The response of bilayer patches to addition of recombinant ANXA7 or ALG-2 
(produced as previously described) was monitored at 22 °C with time-lapse epi-fluorescence microscopy using 
a Nikon TE2000 inverted microscope (40X objective, Nikon ELWD, Plan Fluor, NA = 0.6) and DiD-excitation 
with a Xenon lamp (Polychrome V, Till Photonics) at 640 nm and recorded with an EMCCD camera (Sensicam 
EM, PCO) operated with Live Acquisition software (FEI, GmbH). ANXA7 and ALG-2 in an absolute amount 
of 100 pmole was added to the fluid cell and the sample imaged at 3–10 fps depending on the response speed. 
GFP-labeled ANXA7 or ALG-2 were imaged simultaneously to DiD using a dual wavelength filtercube.
Data Availability
All data are available on request.
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